Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Toth Financial Advisory Corp

Toth Financial Advisory Corp grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,250 shares of the biopharmaceutical company’s stock after buying an additional 3,750 shares during the quarter. Toth Financial Advisory Corp’s holdings in Catalyst Pharmaceuticals were worth $1,132,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of CPRX. GAMMA Investing LLC grew its stake in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $50,000. Larson Financial Group LLC grew its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $134,000. Finally, Quantbot Technologies LP acquired a new position in shares of Catalyst Pharmaceuticals in the third quarter valued at approximately $151,000. 79.22% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 12,000 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the sale, the insider now directly owns 51,391 shares of the company’s stock, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 79,500 shares of company stock worth $1,754,140 in the last 90 days. Company insiders own 11.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. StockNews.com cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 11th. HC Wainwright upped their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Stephens began coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective for the company. Truist Financial upped their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Catalyst Pharmaceuticals has a consensus rating of “Buy” and an average price target of $32.86.

Catalyst Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ CPRX opened at $22.55 on Friday. The stock has a market cap of $2.69 billion, a PE ratio of 19.11, a price-to-earnings-growth ratio of 2.28 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 52-week low of $13.12 and a 52-week high of $24.27. The business has a 50-day moving average price of $21.79 and a 200 day moving average price of $20.45.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.